Understanding high-density lipoprotein function in disease: Recent advances in proteomics unravel the complexity of its composition and biology

Progress in Lipid Research

Volumn 56, Issue 1, 2014, Pages 36-46

  Birner Gruenberger, Ruth ^a,b   Schittmayer, Matthias ^a,b   Holzer, Michael ^a   Marsche, Gunther ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b BIOTECHMED GRAZ   (Austria)

Author keywords

Biomarker; Disease; HDL function; High density lipoprotein; Proteomics

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN C2; APOLIPOPROTEIN M; ARYLDIALKYLPHOSPHATASE 1; CARDIOVASCULAR AGENT; CER 001; CLUSTERIN; COMPLEMENT COMPONENT C3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HAPTOGLOBIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2; PLACEBO; SERUM AMYLOID A; UNCLASSIFIED DRUG; 1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN C3; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; LIPIDOME; VASCULAR CELL ADHESION MOLECULE 1; PROTEOME;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CORONARY ARTERY ATHEROSCLEROSIS; CYTOKINE PRODUCTION; DISEASE MARKER; DOWN REGULATION; FOAM CELL; HEART INFARCTION; HUMAN; LIPIDOMICS; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEOMICS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR ENDOTHELIUM; ARTICLE; BLOOD VESSEL WALL; CHEMICAL COMPOSITION; CHOLESTEROL METABOLISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FUNCTIONAL PROTEOMICS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; RISK ASSESSMENT; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASE; LIPID METABOLISM; METABOLISM; PROCEDURES; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; LIPID METABOLISM; LIPOPROTEINS, HDL; MODELS, BIOLOGICAL; PROTEOME; PROTEOMICS; RISK FACTORS;

EID: 84906702947     PISSN: 01637827     EISSN: 18732194     Source Type: Journal    
DOI: 10.1016/j.plipres.2014.07.003     Document Type: Review

References (137)

1. T. Alonzi, C. Mancone, L. Amicone, and M. Tripodi Elucidation of lipoprotein particles structure by proteomic analysis Expert Rev Proteomics 5 2008 91 104 (Pubitemid 351287744)
2. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, and T.G. Cole et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 1996 1001 1009 (Pubitemid 26338729)
3. J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, and S.M. Cobbe et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630 (Pubitemid 35379733)
4. P. Barter, J. Kastelein, A. Nunn, R. Hobbs Future Forum Editorial Board High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions Atherosclerosis 168 2003 195 211 (Pubitemid 36703318)
5. Emerging Risk Factors Collaboration E. Di Angelantonio, N. Sarwar, P. Perry, S. Kaptoge, and K.K. Ray et al. Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
6. P.P. Toth, P.J. Barter, R.S. Rosenson, W.E. Boden, M.J. Chapman, and M. Cuchel et al. High-density lipoproteins: a consensus statement from the National Lipid Association J Clin Lipidol 7 2013 484 525
7. R.S. Rosenson, H.B. Brewer Jr., B. Ansell, P. Barter, M.J. Chapman, and J.W. Heinecke et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges Circulation 128 2013 1256 1267
8. A.S. Shah, L. Tan, J.L. Long, and W.S. Davidson Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond J Lipid Res 54 2013 2575 2585
9. A. Kontush, M. Lhomme, and M.J. Chapman Unraveling the complexities of the HDL lipidome J Lipid Res 54 2013 2950 2963
10. G. Marsche, M.D. Saemann, A. Heinemann, and M. Holzer Inflammation alters HDL composition and function: implications for HDL-raising therapies Pharmacol Ther 137 2013 341 351
11. G.F. Lewis, and D.J. Rader New insights into the regulation of HDL metabolism and reverse cholesterol transport Circ Res 96 2005 1221 1232 (Pubitemid 40962099)
12. P.G. Yancey, A.E. Bortnick, G. Kellner-Weibel, M. de la Llera-Moya, M.C. Phillips, and G.H. Rothblat Importance of different pathways of cellular cholesterol efflux Arterioscler Thromb Vasc Biol 23 2003 712 719 (Pubitemid 36566157)
13. K.F. Kozarsky, M.H. Donahee, A. Rigotti, S.N. Iqbal, E.R. Edelman, and M. Krieger Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels Nature 387 1997 414 417 (Pubitemid 27227207)
14. R.E. Moore, M. Navab, J.S. Millar, F. Zimetti, S. Hama, and G.H. Rothblat et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation Circ Res 97 2005 763 771 (Pubitemid 41447126)
15. A.S. Plump, C.J. Scott, and J.L. Breslow Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse Proc Natl Acad Sci USA 91 1994 9607 9611 (Pubitemid 24297964)
16. C. Paszty, N. Maeda, J. Verstuyft, and E.M. Rubin Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice J Clin Invest 94 1994 899 903
17. R.K. Tangirala, K. Tsukamoto, S.H. Chun, D. Usher, E. Pure, and D.J. Rader Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice Circulation 100 1999 1816 1822 (Pubitemid 29498389)
18. J.C. Tardif, J. Gregoire, P.L. L'Allier, R. Ibrahim, J. Lesperance, and T.M. Heinonen et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 2007 1675 1682 (Pubitemid 46631626)
19. S.E. Nissen, T. Tsunoda, E.M. Tuzcu, P. Schoenhagen, C.J. Cooper, and M. Yasin et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300 (Pubitemid 37430562)
20. R. Waksman, R. Torguson, K.M. Kent, A.D. Pichard, W.O. Suddath, and L.F. Satler et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome J Am Coll Cardiol 55 2010 2727 2735
21. J.A. Shaw, A. Bobik, A. Murphy, P. Kanellakis, P. Blombery, and N. Mukhamedova et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque Circ Res 103 2008 1084 1091
22. A.R. Tall, L. Yvan-Charvet, N. Terasaka, T. Pagler, and N. Wang HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis Cell Metab 7 2008 365 375 (Pubitemid 351598023)
23. M. Krieger Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems J Clin Invest 108 2001 793 797 (Pubitemid 32880286)
24. H.Y. Lim, C.H. Thiam, K.P. Yeo, R. Bisoendial, C.S. Hii, and K.C. McGrath et al. Lymphatic vessels are essential for the removal of cholesterol from peripheral tissues by SR-BI-mediated transport of HDL Cell Metab 17 2013 671 684
25. C. Martel, W. Li, B. Fulp, A.M. Platt, E.L. Gautier, and M. Westerterp et al. Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice J Clin Invest 123 2013 1571 1579
26. C.L. Vrins, R. Ottenhoff, K. van den Oever, D.R. de Waart, J.K. Kruyt, and Y. Zhao et al. Trans-intestinal cholesterol efflux is not mediated through high density lipoprotein J Lipid Res 53 2012 2017 2023
27. M. Vergeer, S.J. Korporaal, R. Franssen, I. Meurs, R. Out, and G.K. Hovingh et al. Genetic variant of the scavenger receptor BI in humans N Engl J Med 364 2011 136 145
28. P.J. Barter, S. Nicholls, K.A. Rye, G.M. Anantharamaiah, M. Navab, and A.M. Fogelman Antiinflammatory properties of HDL Circ Res 95 2004 764 772 (Pubitemid 39390578)
29. D. Hine, B. Mackness, and M. Mackness Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation IUBMB Life 64 2012 157 161
30. A. Kontush, and M.J. Chapman Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities Curr Opin Lipidol 21 2010 312 318
31. G.W. Cockerill, K.A. Rye, J.R. Gamble, M.A. Vadas, and P.J. Barter High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules Arterioscler Thromb Vasc Biol 15 1995 1987 1994
32. M. Westerterp, A.E. Bochem, L. Yvan-Charvet, A.J. Murphy, N. Wang, and A.R. Tall ATP-binding cassette transporters, atherosclerosis, and inflammation Circ Res 114 2014 157 170
33. A.R. Tall, L. Yvan-Charvet, M. Westerterp, and A.J. Murphy Cholesterol efflux: a novel regulator of myelopoiesis and atherogenesis Arterioscler Thromb Vasc Biol 32 2012 2547 2552
34. M. Westerterp, A.J. Murphy, M. Wang, T.A. Pagler, Y. Vengrenyuk, and M.S. Kappus et al. Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice Circ Res 112 2013 1456 1465
35. X. Zhu, J.Y. Lee, J.M. Timmins, J.M. Brown, E. Boudyguina, and A. Mulya et al. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages J Biol Chem 283 2008 22930 22941
36. L. Yvan-Charvet, C. Welch, T.A. Pagler, M. Ranalletta, M. Lamkanfi, and S. Han et al. Increased inflammatory gene expression in ABC transporter- deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions Circulation 118 2008 1837 1847
37. A.M. Whetzel, J.M. Sturek, M.H. Nagelin, D.T. Bolick, A.K. Gebre, and J.S. Parks et al. ABCG1 deficiency in mice promotes endothelial activation and monocyte-endothelial interactions Arterioscler Thromb Vasc Biol 30 2010 809 817
38. D. De Nardo, L.I. Labzin, H. Kono, R. Seki, S.V. Schmidt, and M. Beyer et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3 Nat Immunol 15 2014 152 160
39. J.R. Nofer, M. van der Giet, M. Tolle, I. Wolinska, K. von Wnuck Lipinski, and H.A. Baba et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3 J Clin Invest 113 2004 569 581 (Pubitemid 38542506)
40. I.S. Yuhanna, Y. Zhu, B.E. Cox, L.D. Hahner, S. Osborne-Lawrence, and P. Lu et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase Nat Med 7 2001 853 857 (Pubitemid 32691642)
41. C. Mineo, I.S. Yuhanna, M.J. Quon, and P.W. Shaul High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases J Biol Chem 278 2003 9142 9149 (Pubitemid 36800395)
42. N. Terasaka, S. Yu, L. Yvan-Charvet, N. Wang, N. Mzhavia, and R. Langlois et al. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet J Clin Invest 118 2008 3701 3713
43. L. Calabresi, G. Franceschini, C.R. Sirtori, A. De Palma, M. Saresella, and P. Ferrante et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins Biochem Biophys Res Commun 238 1997 61 65 (Pubitemid 27453274)
44. S. Blankenberg, S. Barbaux, and L. Tiret Adhesion molecules and atherosclerosis Atherosclerosis 170 2003 191 203 (Pubitemid 37377790)
45. P.J. Patel, A.V. Khera, K. Jafri, R.L. Wilensky, and D.J. Rader The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease J Am Coll Cardiol 58 2011 2068 2075
46. J.E. Feig, J.X. Rong, R. Shamir, M. Sanson, Y. Vengrenyuk, and J. Liu et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells Proc Natl Acad Sci USA 108 2011 7166 7171
47. J. Julve, J.C. Escola-Gil, N. Rotllan, C. Fievet, E. Vallez, and C. de la Torre et al. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome Arterioscler Thromb Vasc Biol 30 2010 232 238
48. V. Adams, C. Besler, T. Fischer, M. Riwanto, F. Noack, and R. Hollriegel et al. Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties Circ Res 113 2013 1345 1355
49. C. Besler, K. Heinrich, L. Rohrer, C. Doerries, M. Riwanto, and D.M. Shih et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease J Clin Invest 121 2011 2693 2708
50. M. Holzer, K. Zangger, D. El-Gamal, V. Binder, S. Curcic, and V. Konya et al. Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein Antioxid Redox Signal 17 2012 1043 1052
51. C. Besler, T.F. Luscher, and U. Landmesser Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease EMBO Mol Med 4 2012 251 268
52. G. Marsche, R. Heller, G. Fauler, A. Kovacevic, A. Nuszkowski, and W. Graier et al. 2-Chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis Arterioscler Thromb Vasc Biol 24 2004 2302 2306 (Pubitemid 39658033)
53. C. Mineo, and P.W. Shaul Novel biological functions of high-density lipoprotein cholesterol Circ Res 111 2012 1079 1090
54. T.F. Luscher, U. Landmesser, A. von Eckardstein, and A.M. Fogelman High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target Circ Res 114 2014 171 182
55. I. Suc, I. Escargueil-Blanc, M. Troly, R. Salvayre, and A. Negre-Salvayre HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL Arterioscler Thromb Vasc Biol 17 1997 2158 2166 (Pubitemid 28057117)
56. M. Riwanto, L. Rohrer, B. Roschitzki, C. Besler, P. Mocharla, and M. Mueller et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling Circulation 127 2013 891 904
57. J.R. Nofer, B. Levkau, I. Wolinska, R. Junker, M. Fobker, and A. von Eckardstein et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids J Biol Chem 276 2001 34480 34485
58. J.E. Feig, B. Hewing, J.D. Smith, S.L. Hazen, and E.A. Fisher High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies Circ Res 114 2014 205 213
59. B. Hewing, K.J. Moore, and E.A. Fisher HDL and cardiovascular risk: time to call the plumber? Circ Res 111 2012 1117 1120
60. B.F. Voight, G.M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, and M.K. Jensen et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study Lancet 380 2012 572 580
61. G. Silbernagel, B. Schottker, S. Appelbaum, H. Scharnagl, M.E. Kleber, and T.B. Grammer et al. High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality Eur Heart J 34 2013 3563 3571
62. E.M. deGoma, R.L. deGoma, and D.J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches J Am Coll Cardiol 51 2008 2199 2211 (Pubitemid 351754991)
63. W. Annema, and A. von Eckardstein High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis Circ J 77 2013 2432 2448
64. M. Triolo, W. Annema, R.P. Dullaart, and U.J. Tietge Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research Biomark Med 7 2013 457 472
65. Y. Zhang, J.R. Da Silva, M. Reilly, J.T. Billheimer, G.H. Rothblat, and D.J. Rader Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo J Clin Invest 115 2005 2870 2874 (Pubitemid 41434414)
66. A.V. Khera, P.J. Patel, M.P. Reilly, and D.J. Rader The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality J Am Coll Cardiol 62 2013 1909 1910
67. H. Jafri, A.A. Alsheikh-Ali, P. Mooney, C.D. Kimmelstiel, R.H. Karas, and J.T. Kuvin Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD J Clin Lipidol 3 2009 45 50
68. R.H. Mackey, P. Greenland, D.C. Goff Jr., D. Lloyd-Jones, C.T. Sibley, and S. Mora High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis) J Am Coll Cardiol 60 2012 508 516
69. J.A. DiDonato, Y. Huang, K.S. Aulak, O. Even-Or, G. Gerstenecker, and V. Gogonea et al. Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma Circulation 128 2013 1644 1655
70. Y. Huang, J.A. Didonato, B.S. Levison, D. Schmitt, L. Li, and Y. Wu et al. An abundant dysfunctional apolipoprotein A1 in human atheroma Nat Med 20 2014 193 203
71. M. Holzer, M. Gauster, T. Pfeifer, C. Wadsack, G. Fauler, and P. Stiegler et al. Protein carbamylation renders high-density lipoprotein dysfunctional Antioxid Redox Signal 14 2011 2337 2346
72. B.J. Van Lenten, S.Y. Hama, F.C. de Beer, D.M. Stafforini, T.M. McIntyre, and S.M. Prescott et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures J Clin Invest 96 1995 2758 2767
73. M. Tolle, T. Huang, M. Schuchardt, V. Jankowski, N. Prufer, and J. Jankowski et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A Cardiovasc Res 94 2012 154 162
74. T. Weichhart, C. Kopecky, M. Kubicek, M. Haidinger, D. Doller, and K. Katholnig et al. Serum amyloid A in uremic HDL promotes inflammation J Am Soc Nephrol 23 2012 934 947
75. M. Holzer, P. Wolf, S. Curcic, R. Birner-Gruenberger, W. Weger, and M. Inzinger et al. Psoriasis alters HDL composition and cholesterol efflux capacity J Lipid Res 53 2012 1618 1624
76. M. Holzer, R. Birner-Gruenberger, T. Stojakovic, D. El-Gamal, V. Binder, and C. Wadsack et al. Uremia alters HDL composition and function J Am Soc Nephrol 22 2011 1331 1341
77. J.C. Tardif, C.M. Ballantyne, P. Barter, J.L. Dasseux, Z.A. Fayad, and M.C. Guertin et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial Eur Heart J 2014 (in press)
78. J.H. Levels, D. Pajkrt, M. Schultz, F.J. Hoek, A. van Tol, and J.C. Meijers et al. Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis Biochim Biophys Acta 1771 2007 1429 1438
79. B.G. Drew, A.L. Carey, A.K. Natoli, M.F. Formosa, D. Vizi, and M. Reddy-Luthmoodoo et al. Reconstituted high-density lipoprotein infusion modulates fatty acid metabolism in patients with type 2 diabetes mellitus J Lipid Res 52 2011 572 581
80. T. Vaisar, S. Pennathur, P.S. Green, S.A. Gharib, A.N. Hoofnagle, and M.C. Cheung et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL J Clin Invest 117 2007 746 756 (Pubitemid 46348533)
81. M.P. Reilly, and A.R. Tall HDL proteomics: pot of gold or Pandora's box? J Clin Invest 117 2007 595 598 (Pubitemid 46348516)
82. I. Sreckovic, R. Birner-Gruenberger, B. Obrist, T. Stojakovic, H. Scharnagl, and M. Holzer et al. Distinct composition of human fetal HDL attenuates its anti-oxidative capacity Biochim Biophys Acta 1831 2013 737 746
83. M. Holzer, M. Trieb, V. Konya, C. Wadsack, A. Heinemann, and G. Marsche Aging affects high-density lipoprotein composition and function Biochim Biophys Acta 1831 2013 1442 1448
84. K. Alwaili, D. Bailey, Z. Awan, S.D. Bailey, I. Ruel, and A. Hafiane et al. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile Biochim Biophys Acta 1821 2011 405 415
85. A. Mange, A. Goux, S. Badiou, L. Patrier, B. Canaud, and T. Maudelonde et al. HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approach PLoS One 7 2012 e34107
86. J. Watanabe, C. Charles-Schoeman, Y. Miao, D. Elashoff, Y.Y. Lee, and G. Katselis et al. Proteomic profiling following immunoaffinity capture of HDL: association of acute phase proteins and complement factors with pro-inflammatory HDL in rheumatoid arthritis Arthritis Rheum 64 2012 1828 1837
87. A.N. Hoofnagle, J.O. Becker, M.N. Oda, G. Cavigiolio, P. Mayer, and T. Vaisar Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures Clin Chem 58 2012 777 781
88. H.N. Yassine, A.M. Jackson, C.R. Borges, D. Billheimer, H. Koh, and D. Smith et al. The application of multiple reaction monitoring and multi-analyte profiling to HDL proteins Lipids Health Dis 13 2014 8 10.1186/1476-511X-13-8
89. S.M. Gordon, W.S. Davidson, E.M. Urbina, L.M. Dolan, A. Heink, and H. Zang et al. The effects of type 2 diabetes on lipoprotein composition and arterial stiffness in male youth Diabetes 62 2013 2958 2967
90. G. Marsche, M. Holzer, and P. Wolf Anti-psoriatic treatment extends beyond the skin: recovering of high-density lipoprotein function Exp Dermatol 2014 (in press)
91. G. Marhaug, and G. Husby Serum amyloid A protein in high density lipoprotein fraction of human acute phase serum Lancet 2 1982 1463
92. D. Sviridov, A. Hoang, W.H. Sawyer, and N.H. Fidge Identification of a sequence of apolipoprotein A-I associated with the activation of lecithin: cholesterol acyltransferase J Biol Chem 275 2000 19707 19712 (Pubitemid 30441567)
93. R.C. Sorenson, C.L. Bisgaier, M. Aviram, C. Hsu, S. Billecke, and B.N. La Du Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity Arterioscler Thromb Vasc Biol 19 1999 2214 2225 (Pubitemid 29422255)
94. G. Castro, L.P. Nihoul, C. Dengremont, C. de Geitere, B. Delfly, and A. Tailleux et al. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport Biochemistry 36 1997 2243 2249 (Pubitemid 27104718)
95. S. Zhong, I.J. Goldberg, C. Bruce, E. Rubin, J.L. Breslow, and A. Tall Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice J Clin Invest 94 1994 2457 2467
96. M. Holzer, P. Wolf, M. Inzinger, M. Trieb, S. Curcic, and L. Pasterk et al. Anti-psoriatic therapy recovers high-density lipoprotein composition and function J Invest Dermatol 134 2014 635 642
97. A. Artl, G. Marsche, S. Lestavel, W. Sattler, and E. Malle Role of serum amyloid A during metabolism of acute-phase HDL by macrophages Arterioscler Thromb Vasc Biol 20 2000 763 772 (Pubitemid 30151692)
98. G.A. Coetzee, A.F. Strachan, D.R. van der Westhuyzen, H.C. Hoppe, M.S. Jeenah, and F.C. de Beer Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition J Biol Chem 261 1986 9644 9651 (Pubitemid 17214087)
99. E. Malle, and F.C. De Beer Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice Eur J Clin Invest 26 1996 427 435 (Pubitemid 26226404)
100. T. Chiba, M.Y. Chang, S. Wang, T.N. Wight, T.S. McMillen, and J.F. Oram et al. Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans Arterioscler Thromb Vasc Biol 31 2011 1326 1332
101. R. Badolato, J.M. Wang, W.J. Murphy, A.R. Lloyd, D.F. Michiel, and L.L. Bausserman et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes J Exp Med 180 1994 203 209 (Pubitemid 24181069)
102. M.C. de Beer, F.C. de Beer, C.J. Gerardot, D.R. Cecil, N.R. Webb, and M.L. Goodson et al. Structure of the mouse Saa4 gene and its linkage to the serum amyloid A gene family Genomics 34 1996 139 142 (Pubitemid 26159886)
103. R.C. Strunk, K.S. Kunke, and P.C. Giclas Human peripheral blood monocyte-derived macrophages produce haemolytically active C3 in vitro Immunology 49 1983 169 174 (Pubitemid 13120377)
104. R. Oksjoki, P.T. Kovanen, and M.O. Pentikainen Role of complement activation in atherosclerosis Curr Opin Lipidol 14 2003 477 482 (Pubitemid 37297302)
105. J. Watanabe, V. Grijalva, S. Hama, K. Barbour, F.G. Berger, and M. Navab et al. Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein J Biol Chem 284 2009 18292 18301
106. P.H. Green, R.M. Glickman, J.W. Riley, and E. Quinet Human apolipoprotein A-IV. Intestinal origin and distribution in plasma J Clin Invest 65 1980 911 919 (Pubitemid 10144067)
107. I.J. Goldberg, C.A. Scheraldi, L.K. Yacoub, U. Saxena, and C.L. Bisgaier Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV J Biol Chem 265 1990 4266 4272
108. A. Steinmetz, and G. Utermann Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV J Biol Chem 260 1985 2258 2264 (Pubitemid 15105725)
109. H. Inadera, A. Hibino, J. Kobayashi, T. Kanzaki, K. Shirai, and S. Yukawa et al. A missense mutation (Trp - >26Arg) in exon 3 of the apolipoprotein CII gene in a patient with apolipoprotein CII deficiency (apo CII-Wakayama) Biochem Biophys Res Commun 193 1993 1174 1183 (Pubitemid 23209718)
110. M.C. Jong, M.H. Hofker, and L.M. Havekes Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3 Arterioscler Thromb Vasc Biol 19 1999 472 484 (Pubitemid 29135144)
111. A. Kawakami, M. Osaka, M. Aikawa, S. Uematsu, S. Akira, and P. Libby et al. Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation Circ Res 103 2008 1402 1409
112. A. Kawakami, M. Osaka, M. Tani, H. Azuma, F.M. Sacks, and K. Shimokado et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction Circulation 118 2008 731 742
113. M.K. Jensen, E.B. Rimm, J.D. Furtado, and F.M. Sacks Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease J Am Heart Assoc 1 2012 10.1161/JAHA.111.000232 [Epub 2012 Apr 24]
114. E.M. Ooi, D.T. Chan, G.F. Watts, D.C. Chan, T.W. Ng, and G.K. Dogra et al. Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease J Lipid Res 52 2011 794 800
115. M. Sevvana, J. Ahnstrom, C. Egerer-Sieber, H.A. Lange, B. Dahlback, and Y.A. Muller Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M J Mol Biol 393 2009 920 936
116. R. Karuna, R. Park, A. Othman, A.G. Holleboom, M.M. Motazacker, and I. Sutter et al. Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism Atherosclerosis 219 2011 855 863
117. J.R. Nofer Hyperlipidaemia and cardiovascular disease: HDL, inflammation and surprising results of AIM-HIGH study Curr Opin Lipidol 23 2012 260 262
118. C. Wolfrum, M.N. Poy, and M. Stoffel Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis Nat Med 11 2005 418 422 (Pubitemid 40562332)
119. C. Christoffersen, M. Jauhiainen, M. Moser, B. Porse, C. Ehnholm, and M. Boesl et al. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice J Biol Chem 283 2008 1839 1847
120. S.E. Jones, and C. Jomary Clusterin Int J Biochem Cell Biol 34 2002 427 431 (Pubitemid 34242756)
121. A.N. Hoofnagle, M. Wu, A.K. Gosmanova, J.O. Becker, E.M. Wijsman, and J.D. Brunzell et al. Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia Arterioscler Thromb Vasc Biol 30 2010 2528 2534
122. H. Moradi, M.V. Pahl, R. Elahimehr, and N.D. Vaziri Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease Transl Res 153 2009 77 85
123. N.D. Vaziri, H. Moradi, M.V. Pahl, A.M. Fogelman, and M. Navab In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide Kidney Int 76 2009 437 444
124. N.D. Vaziri, K. Navab, P. Gollapudi, H. Moradi, M.V. Pahl, and C.H. Barton et al. Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease J Natl Med Assoc 103 2011 524 533
125. B. Mackness, and M. Mackness The antioxidant properties of high-density lipoproteins in atherosclerosis Panminerva Med 54 2012 83 90
126. M. Aviram Atherosclerosis: cell biology and lipoproteins - oxidative stress and paraoxonases regulate atherogenesis Curr Opin Lipidol 21 2010 163 164
127. T. Bhattacharyya, S.J. Nicholls, E.J. Topol, R. Zhang, X. Yang, and D. Schmitt et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk JAMA 299 2008 1265 1276 (Pubitemid 351439073)
128. R.S. Rosenson, H.B. Brewer Jr., W.S. Davidson, Z.A. Fayad, V. Fuster, and J. Goldstein et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport Circulation 125 2012 1905 1919
129. R.S. Rosenson, and D.M. Stafforini Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2 J Lipid Res 53 2012 1767 1782
130. M.C. Cheung, and J.J. Albers Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II J Biol Chem 259 1984 12201 12209 (Pubitemid 14019758)
131. R.S. Rosenson, H.B. Brewer Jr., M.J. Chapman, S. Fazio, M.M. Hussain, and A. Kontush et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events Clin Chem 57 2011 392 410
132. L. Camont, M. Lhomme, F. Rached, W. Le Goff, A. Negre-Salvayre, and R. Salvayre et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities Arterioscler Thromb Vasc Biol 33 2013 2715 2723
133. M. Stahlman, B. Fagerberg, M. Adiels, K. Ekroos, J.M. Chapman, and A. Kontush et al. Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles Biochim Biophys Acta 1831 2013 1609 1617
134. S. Deakin, X. Moren, and R.W. James HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity Arterioscler Thromb Vasc Biol 27 2007 1146 1152 (Pubitemid 46641970)
135. G. Marsche, A. Hammer, O. Oskolkova, K.F. Kozarsky, W. Sattler, and E. Malle Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport J Biol Chem 277 2002 32172 32179 (Pubitemid 34969031)
136. G. Marsche, P.G. Furtmuller, C. Obinger, W. Sattler, and E. Malle Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro Cardiovasc Res 79 2008 187 194 (Pubitemid 351881925)
137. C. Bergt, S. Pennathur, X. Fu, J. Byun, K. O'Brien, and T.O. McDonald et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport Proc Natl Acad Sci USA 101 2004 13032 13037 (Pubitemid 39167578)